FierceBiotech ٢ يونيو ٢٠٢٦ Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
FDA News Releases ٢ يونيو ٢٠٢٦ FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
FierceBiotech ٢ يونيو ٢٠٢٦ ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
FierceBiotech ٢ يونيو ٢٠٢٦ ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
FierceBiotech ٢ يونيو ٢٠٢٦ MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
Novartis ٢ يونيو ٢٠٢٦ ASCO26: Celcuity's drug halves risk of disease progression, death versus Novartis' Piqray in PIK3CA-mutant breast cancer - FirstWord Pharma
Endpoints News ٢ يونيو ٢٠٢٦ #ASCO26: Celcuity plans another FDA filing after positive breast cancer readout